Replies to post #39906 on Humanigen Inc (fka HGENQ)

[cowtown jay]

If Gilead is scrapping their late-stage study of magrolimab with azacitidine to treat blood cancer, I wonder how that bodes for the other half dozen or so trials using that drug combination.

https://clinicaltrials.gov/search?intr=Magrolimab&viewType=Table&page=1

Lenzilumab with azacitidine was the drug combination that resulted in our successful CMML study.

https://www.newsfilecorp.com/release/169164/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACHM-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-European-Hematology-Association-Congress